Literature DB >> 10890190

Cavernous sinus invasion and tumor proliferative potential of growth hormone-producing pituitary tumors.

S Iuchi1, N Saeki, Y Uchino, Y Higuchi, I Tatsuno, S Nakamura, T Yasuda, A Yamaura.   

Abstract

PURPOSE: Surgical removal of growth hormone-producing pituitary adenomas (GHomas) becomes difficult when they invade the cavernous sinus (CS). We investigated the relation among tumor proliferative potential, tumor volume and invasion of GHomas to CS. MATERIALS &
METHODS: 15 patients with GHoma aged 20-59 years were enrolled. The volumes of the adenomas were calculated from MR images and the extension to CS was classified into 5 grades according to Knosp's grading system. The immuno-histochemical staining for anti-Ki-67 monoclonal antibody (MIB-1) was performed and the proliferative potential of GHomas was determined as the percentage of MIB-1 labeled nuclei (MIB-1 index). The volume, MIB-1 index and pre-operative growth hormone (GH) level were compared with CS invasion by single and multiple regression analyses.
RESULTS: With single regression analyses, CS invasion was significantly correlated with both the volume (r=0.69, p<0.01) and MIB-1 index (r=0.73, p<0.01), but not with the GH level (r=0.42, p=0.12). The volume and MIB-1 index showed a weak correlation but it was not significant (r=0.52, p=0.06). With multiple regression analysis, CS invasion was well explained by the volume and MIB-1 index of GHomas (r=0.82, p<0.01). About 66% of CS invasion was explained by these two factors.
CONCLUSIONS: In view of these results, not only the volume but also the speed of growth are important for GHomas to invade CS. GHomas with a high MIB-1 index may, even if they are small, more readily invade CS and need closer post-operative hormonal and neuroimaging studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890190     DOI: 10.1507/endocrj.47.supplmarch_s77

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

Review 1.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Expression of laminin beta2: a novel marker of hypoxia in pituitary adenomas.

Authors:  Yijun Bao; Daizo Yoshida; Daijiro Morimoto; Akira Teramoto
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

3.  Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.

Authors:  Leila Hedayati Zafarghandi; Mohammad Ebrahim Khamseh; Milad Fooladgar; Shahrzad Mohseni; Mostafa Qorbani; Nahid Hashemi Madani; Mahboobeh Hemmatabadi; MohammadReza Mohajeri-Tehrani; Nooshin Shirzad
Journal:  J Diabetes Metab Disord       Date:  2020-04-05

4.  A Nomogram for Preoperatively Predicting the Ki-67 Index of a Pituitary Tumor: A Retrospective Cohort Study.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Feng Yuan; Zixiang Cong; Chiyuan Ma
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.